Levetiracetam Sandoz

Levetiracetam, the active ingredient in Levetiracetam Sandoz, is an anticonvulsant presented as an oral tablet for oral use. It is indicated for the treatment of partial, generalized tonic‑clonic and myoclonic seizures in patients diagnosed with epilepsy, helping to reduce seizure frequency and improve neurological stability.

GNH USA supplies Levetiracetam Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with European Union regulatory standards and is manufactured under GMP conditions, ensuring consistent purity and potency for global distribution.

Levetiracetam is an antiepileptic drug used to manage seizure disorders by stabilizing neuronal activity.

Partial seizures: reduces frequency of focal onset seizures, improving control of focal motor or sensory events. Generalized tonic‑clonic seizures: helps prevent bilateral convulsive episodes in patients with generalized epilepsy. Myoclonic seizures: diminishes rapid, brief muscle jerks associated with juvenile myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent tiredness not relieved by rest. - Somnolence: increased sleepiness during daytime. - Irritability or mood changes: heightened emotional reactivity. - Headache: mild to moderate cranial pain. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Severe allergic reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis): may present with skin rash, blistering, and mucosal involvement. - Psychiatric disturbances (aggression, depression, suicidal ideation): require immediate medical evaluation.

When prescribing or dispensing Levetiracetam, consider the following precautions.

Dose adjustment: renal impairment may require reduced dosage based on creatinine clearance. Pregnancy: safety not established; use only if potential benefit justifies risk. Concomitant CNS depressants: monitor for additive sedation. Behavioral changes: observe patients for new irritability or mood swings. Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Levetiracetam can interact with several medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Carbamazepine: enzyme induction may lower levetiracetam plasma levels. - Phenobarbital: hepatic enzyme induction may reduce efficacy. - Phenytoin: may decrease levetiracetam concentrations.

Moderate Interactions (Monitor Closely): - Alcohol: additive CNS depression may increase dizziness. - Other antiepileptics (valproate, topiramate): monitor seizure control. - Antidepressants (SSRIs): watch for increased behavioral side effects.